CERo Therapeutics Holdings, Inc. is a biotech firm dedicated to pioneering advanced engineered T-cell immunotherapies for the treatment of various cancers. Their leading therapeutic candidate, CER-1236, is an autologous T-cell therapy currently in development, aimed at addressing both blood cancers (hematologic malignancies) and solid tumors. This company was founded in 2021 and is headquartered in South San Francisco, California.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 1.21M shares outstanding
USCERo Therapeutics Holdings, Inc. is a biotech firm dedicated to pioneering advanced engineered T-cell immunotherapies for the treatment of various cancers. Their leading therapeutic candidate, CER-1236, is an autologous T-cell therapy currently in development, aimed at addressing both blood cancers (hematologic malignancies) and solid tumors. This company was founded in 2021 and is headquartered in South San Francisco, California.
Brian G. Atwood
Chairman and Chief Executive Officer
Daniel Corey
Chief Technology Officer
Christopher Ehrlich
Chief Executive Officer & Chair
Andrew Albert Kucharchuk
Chief Financial Officer
Employees
8
Country
US
Sector
Healthcare
Website
cero.bio
Loading congressional disclosures…
based on 1.21M shares outstanding
US30d Avg
505.60K
60d Avg
634.11K
90d Avg
597.60K
